|Mr. Jack Weinstein||CFO & Treasurer||N/A||N/A||1956|
|Mr. Jeremy Meinen||VP of Fin. & Admin.||N/A||N/A||N/A|
|Dr. Gilles Della Corte||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Christiaan L. J. J. Stijnen||Chief Commercial Officer||N/A||N/A||N/A|
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.
Relief Therapeutics Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.